Neuronetics Announces Appointment of Robert Cascella to its Board of Directors
April 01 2021 - 4:05PM
Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical
technology company focused on designing, developing and marketing
products that improve the quality of life for patients who suffer
from psychiatric disorders, today announced the appointment of
Robert A. Cascella to its Board of Directors, effective
immediately. Following his appointment, the Neuronetics’ Board of
Directors now has eight members.
“I am very pleased to have a leader of Rob’s quality and
experience join Neuronetics’ Board of Directors,” said Keith
Sullivan, President and Chief Executive Officer of Neuronetics,
Inc. “His history of value creation in healthcare uniquely
qualifies him to help guide Neuronetics as we continue to build
upon our market leadership position.”Mr. Cascella brings more than
three decades of leadership experience within the healthcare
sector. He joined Royal Philips NV in 2015 and currently serves as
a Special Advisor to the Company. Prior to this advisory role, Mr.
Cascella served as Executive Vice President and Strategic Business
Development Leader and member of the Executive Committee at
Philips. Mr. Cascella has also held several other leadership roles
at Philips, including Chief Business Leader for the Precision
Diagnosis Segment, and Chief Business Leader of the Diagnosis and
Treatment Segment. Prior to joining Philips, Mr. Cascella spent 11
years at Hologic, serving as President and then later as Chief
Executive Officer. He also currently serves on the Board of
Directors of Celestica Inc. and Metabolon, Inc. “I'm honored and
excited to join Neuronetics Board of Directors,” said Mr. Cascella.
“NeuroStar Advanced Therapy for Mental Health is a compelling and
effective treatment alternative for patients suffering from
psychiatric disorders. The Company has proven technology, a strong
market position and an exceptional team in place to execute its
long-term growth strategy. Throughout my career, I have been
committed to bringing technologies to market that made a meaningful
difference in the quality of life for patients. I'm looking forward
to bringing this perspective to the Board and help advance
NeuroStar to better support our customers, partners, and most
importantly our
patients.”About NeuroneticsNeuronetics, Inc.
is a commercial-stage medical technology company focused on
designing, developing, and marketing products that improve the
quality of life for patients who suffer from psychiatric disorders.
Its commercial product, the NeuroStar® Advanced Therapy System, is
a non-invasive and non-systemic office-based treatment that uses
transcranial magnetic stimulation, or TMS, to create a pulsed,
MRI-strength magnetic field that induces electrical currents
designed to stimulate specific areas of the brain associated with
mood. The system is cleared by the United States Food and Drug
Administration, or FDA, for the treatment of major depressive
disorder in adult patients who have failed to achieve satisfactory
improvement from prior antidepressant medication in the current
episode. NeuroStar is also available in other parts of the world,
including Japan, where it is listed under Japan’s national health
insurance. Additional information can be found at
www.neuronetics.com.Investor Contact:Mike Vallie
or Mark KlausnerWestwicke
Partners443-213-0499ir@neuronetics.comMedia
Contact:Chelsey MankoVault
Communications610-455-2778cmanko@vaultcommunications.com
Neuronetics (NASDAQ:STIM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Neuronetics (NASDAQ:STIM)
Historical Stock Chart
From Apr 2023 to Apr 2024